New way to deliver antibiotics for lung infections caused by non-tuberculous mycobacteria
Official title: Pulmonary Delivery of Antibiotics Co-crystalized with Cyclodextrin-based Metal Organic Frameworks to Treat Non-Tuberculous Mycobacterial (NTM) Infections
Funded at Scientific Horizons Consulting LLC · NIH-11006740 · Data updated 2026-11-12
This study is testing a new way to deliver antibiotics directly to the lungs for people with non-tuberculous mycobacterial infections, which could make the treatment more effective and cause fewer side effects than the usual methods.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scientific Horizons Consulting LLC NIH-funded |
| Lab location | 1 site (Irvine, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $298,530 |
| NIH project number | 1R43AI186765-01 |
| Project ID | NIH-11006740 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with non-tuberculous mycobacterial lung disease who require antibiotic treatment.
✕Less likely to help
Patients with other types of lung infections or those who do not have NTM lung disease may not benefit from this research.
What this research studies
This research focuses on developing a novel method for delivering antibiotics directly to the lungs to treat non-tuberculous mycobacterial (NTM) infections. By using cyclodextrin-based metal-organic frameworks, the antibiotics are co-crystalized and administered through inhalation, which aims to improve drug delivery while minimizing side effects. The approach seeks to enhance the bioavailability and effectiveness of the antibiotics, allowing for better treatment outcomes with potentially shorter therapy durations. Patients may experience fewer adverse effects compared to traditional high-dose systemic treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective and better-tolerated treatments for patients suffering from NTM lung infections.
How similar studies have gone: While this approach is innovative, similar research has shown promise in improving drug delivery systems for other conditions, indicating potential for success.
Where this research is happening
-
Scientific Horizons Consulting LLC
Irvine, United States Active
Researchers
- Principal investigator: Gao, Xiang — Scientific Horizons Consulting LLC
- Study coordinator: Gao, Xiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.